Eisai, U.S.-Based SuperGen Hit Setback For Leukemia Drug
This article was originally published in PharmAsia News
Executive Summary
Eisai's effort to develop a leukemia drug in the United States suffered a setback when its U.S. partner, SuperGen, reported the drug failed to meet clinical trial endpoints